BULLETIN DU CANCER

Scope & Guideline

Innovative insights shaping the future of oncology.

Introduction

Welcome to your portal for understanding BULLETIN DU CANCER, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageFrench
ISSN0007-4551
PublisherELSEVIER MASSON, CORP OFF
Support Open AccessNo
CountryFrance
TypeJournal
Convergefrom 1966 to 2024
AbbreviationB CANCER / Bull. Cancer
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE

Aims and Scopes

The journal 'Bulletin du Cancer' primarily focuses on disseminating high-quality research and clinical advancements in the field of oncology. It aims to cover a wide spectrum of cancer-related topics, emphasizing not only treatment methodologies but also patient care, public health implications, and the integration of new technologies in cancer management.
  1. Clinical Oncology:
    The journal publishes studies related to the latest clinical practices, treatment protocols, and outcomes across various cancer types, including breast, lung, renal, and hematological malignancies.
  2. Translational Research:
    A significant focus on translational research is evident, with articles addressing the latest findings in cancer biology, drug development, and the application of biomarkers in clinical settings.
  3. Patient-Centered Care:
    Emphasis on patient experiences, quality of life, and shared decision-making processes in cancer care, reflecting a growing recognition of the importance of holistic treatment approaches.
  4. Health Systems and Policy:
    Research exploring the organization and delivery of cancer care, including access to treatments, healthcare disparities, and the integration of supportive care services.
  5. Innovative Therapies and Technologies:
    The journal highlights advancements in innovative therapies such as immunotherapy, CAR-T cell therapy, and the role of artificial intelligence in oncology, showcasing the evolving landscape of cancer treatment.
  6. Epidemiology and Prevention:
    Epidemiological studies that address cancer risk factors, screening practices, and prevention strategies, providing valuable insights into population health and cancer control efforts.
  7. Multidisciplinary Approaches:
    The journal promotes multidisciplinary collaboration in cancer management, emphasizing the roles of various healthcare professionals in improving patient outcomes.
Recent publications in the 'Bulletin du Cancer' have revealed several trending and emerging themes that highlight the evolving landscape of oncology research and practice. These trends reflect the journal's commitment to addressing contemporary challenges and innovations in cancer care.
  1. Immunotherapy and Novel Therapeutics:
    There is a significant increase in research focused on immunotherapy and novel therapeutic agents, including CAR-T cell therapies and immune checkpoint inhibitors, indicating a shift towards more personalized and effective cancer treatments.
  2. Digital Health and Telemedicine:
    The journal is increasingly publishing articles on digital health solutions, telemedicine, and the impact of technology on cancer care delivery, particularly in the context of the COVID-19 pandemic.
  3. Patient Experience and Quality of Life:
    Emerging research themes are focusing on patient experiences and the quality of life of cancer patients, highlighting the importance of patient-centered approaches in oncology.
  4. Health Disparities and Access to Care:
    There is a growing emphasis on studies addressing health disparities, access to care, and the social determinants of health related to cancer treatment, reflecting a broader public health perspective.
  5. Artificial Intelligence in Oncology:
    The incorporation of artificial intelligence and machine learning in oncology research is gaining traction, with studies exploring its potential to improve diagnostic accuracy and treatment personalization.
  6. Survivorship and Long-Term Outcomes:
    An emerging focus on survivorship issues, including long-term outcomes, late effects of treatment, and strategies for improving the quality of life for cancer survivors.

Declining or Waning

While 'Bulletin du Cancer' continues to cover a broad range of oncology topics, certain themes appear to be declining in prominence over recent years. This may reflect shifts in research focus or changes in clinical practice.
  1. Traditional Chemotherapy:
    Research focused solely on traditional chemotherapy regimens is becoming less frequent, as the field shifts towards personalized medicine and targeted therapies.
  2. Single-Institution Studies:
    The prevalence of studies limited to single-institution experiences is decreasing, with a growing emphasis on multi-center collaborations and larger datasets for more robust conclusions.
  3. Basic Science Research:
    There is a noticeable decline in the publication of purely basic science studies, as the journal increasingly prioritizes translational and clinical research that directly impacts patient care.
  4. General Cancer Awareness Campaigns:
    While public health awareness is still important, the journal has reduced the frequency of articles focusing solely on general cancer awareness campaigns, favoring more specific research findings and clinical advancements.

Similar Journals

CANCER

Unveiling breakthroughs in oncology since 1948.
Publisher: WILEYISSN: 0008-543XFrequency: 24 issues/year

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

Cancer Research Communications

Fostering innovation in cancer prevention and therapy.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Journal of the Egyptian National Cancer Institute

Leading the charge in global cancer discourse.
Publisher: SPRINGERISSN: 1110-0362Frequency: 1 issue/year

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Advancing the Frontiers of Cancer Research.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Oncology Letters

Elevating Oncology Discourse for Better Patient Outcomes
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

BRITISH JOURNAL OF CANCER

Elevating the Standards of Cancer Research.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

BREAST

Fostering collaboration for improved patient outcomes.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

INDIAN JOURNAL OF CANCER

Advancing Oncology Knowledge for a Healthier Tomorrow
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0019-509XFrequency: 4 issues/year

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Elevating Clinical Practice with Expert Contributions
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0889-8588Frequency: 6 issues/year

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, published by W B SAUNDERS CO-ELSEVIER INC, is a premier journal dedicated to advancing the fields of hematology and oncology. With its ISSN 0889-8588 and E-ISSN 1558-1977, this esteemed publication has been a cornerstone of clinical scholarship since its inception in 1987, providing comprehensive annual updates that bridge the gap between research and clinical practice. Known for its rigorous editorial standards and impactful contributions, the journal holds a respectable Q2 quartile classification in both hematology and oncology as of 2023, ranking it in the 50th percentile among its peers. Although it is not an open-access journal, the content is accessible to institutions and professionals worldwide. As the scope of the journal expands through 2024, it continues to attract an audience of researchers, healthcare professionals, and students who seek to stay informed on the latest advancements, treatment modalities, and groundbreaking studies in the fields of hematology and oncology.

South Asian Journal of Cancer

Advancing cancer research in South Asia.
Publisher: GEORG THIEME VERLAG KGISSN: 2278-330XFrequency: 4 issues/year

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.